Palisade Bio (PALI) Preferred Stock Liabilities (2020)
Palisade Bio (PALI) reported Preferred Stock Liabilities of $9.5 million for Q4 2020.
Palisade Bio (PALI) Preferred Stock Liabilities (2020) Analysis & Trends
Palisade Bio (PALI) has 1 years of Preferred Stock Liabilities data on file, last reported at $9.5 million in Q4 2020.
- Preferred Stock Liabilities for Q4 2020 came in at $9.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was $9.5 million (changed N/A YoY), and the FY2020 annual result was $9.5 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $9.5 million in Q4 2020 per PALI's latest filing.
- Over five years, Preferred Stock Liabilities peaked at $9.5 million in Q4 2020 and troughed at $9.5 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Palisade Bio | 391.02 Mn | 261.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 9.50 Mn |